• United-Guardian annual report for FY-2025 flagged weaker overall performance as cosmetic ingredient demand slowed, partly tied to distributor inventory overhang and softer conditions in China.
• Pharmaceutical business strengthened, led by higher Renacidin volumes across national wholesalers.
• Company secured formulary access with 2 major pharmacy benefit managers, aiming to expand patient coverage for Renacidin.
• Medical lubricants business grew on higher demand from 2 large contract manufacturing customers in China.
• Management targeted renewed personal care growth through new distribution agreements covering South Korea and France, with an updated Ashland marketing agreement expected in first half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United-Guardian Inc. published the original content used to generate this news brief on April 22, 2026, and is solely responsible for the information contained therein.